Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"
The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the press and the medical community for its ability to trigger profound weight loss.
Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...
Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback